Table 2.

Univariate analysis of overall survival of NSCLC patients with BM.

Variable	N	OS(median)	95%CI	P
	586	15.400	14.064–16.736
Gender				0.808
Male	375	16.533	14.823–18.244
Female	211	14.733	12.203–17.264
Age				0.019
<70	532	16.267	14.783–17.751
≥70	54	11.067	8.798–13.336
Smoking status				0.008
Never	305	17.500	14.756–20.244
Ever	281	14.700	12.892–16.508
Histology				0.911
AC1	513	15.500	14.065–16.935
NAC2	73	14.967	9.418–20.516
EGFR mutation				0.087
Wild	57	25.933	18.351–33.516
Mutant	52	35.100	30.127–40.073
KPS3				<0.001
<70	201	10.700	8.313–13.087
70–80	295	17.133	14.997–19.270
≥90	90	34.300	23.356–45.244
Number of BM				0.006
≤3	395	16.767	14.779–18.755
>3	191	13.300	11.189–15.411
Size of BM4				0.082
<1.2 cm	285	16.933	14.275–19.592
≥1.2 cm	301	14.933	13.535–16.332
Extracraninal metastases				<0.001
No	264	19.933	16.011–23.8565
Yes	322	13.267	11.415–15.118
N stage				<0.001
N0	173	25.900	18.811–32.989
N1	136	21.500	16.231–26.769	0.146
N2	160	10.367	7.083–13.651	<0.001
N3	117	9.700	8.351–11.04	0.256
Traditional GPA5 scores				<0.001
Class A:0–1	160	10.633	8.939–12.327
Class B:1.5–2	211	16.267	14.196–18.337	<0.001
Class C:2.5–3	171	118.833	16.210–21.457	0.347
Class D:3.5–4	44	74.900	23.568–126.232	<0.001
Treatment modality				<0.001
Symptomatic treatment6	78	8.567	5.675–11.459
Conventional therapy7	307	12.800	10.875–14.725
TKIs therapy8	201	29.667	25.318–34.015

¹AC, adenocarcinoma; ²NAC, non-adenocarcinoma; ³KPSm Karnofsky performance status; ⁴size of BM, median diameter of the largest brain metastasis; ⁵GPA, graded prognostic assessment; ⁶Symptomatic treatment, reducing intracranial pressure treatment: Mannitol 125mg/time, twice every day, intravenous drip; ⁷Conventional therapy, systemic chemotherapy plus local treatment; ⁸TKIs therapy, first generation of tyrosine kinase inhibitors (TKIs): gefitinib or erlotinib.